Skip to main content
FDA OKs pexidartinib to treat tenosynovial giant cell tumor

Daiichi Sankyo's Turalio, or pexidartinib, received FDA approval as a treatment for adults with tenosynovial giant cell tumor, a rare, non-cancerous tumor that affects a patient's joints and limbs. A boxed warning is included in its label warning of the potential risk for serious and possibly fatal liver injury.

Full Story: